Newsfeeds - Spark Newswire

1 minute read

Navidea Biopharmaceuticals Announces Resignation Of Jed A. Latkin

Today, 3:47 PM

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the

NAVB

2 minute read

Earnings

Looking Into Navidea Biopharmaceutical’s Return On Capital Employed

By Benzinga Insights

Today, 3:47 PM

According to Benzinga Pro data, during Q2, Navidea Biopharmaceutical (AMEX:NAVB) posted sales of $261.05 thousand. Earnings were up 19.83%, but Navidea Biopharmaceutical still reported an overall loss of $2.67 million.

NAVB

2 minute read

4 Penny Stocks Insiders Are Buying

By Lisa Levin

Today, 3:47 PM

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AVTX

5 minute read

The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering

By Shanthi Rexaline

Today, 3:47 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)

ACAD

11 minute read

Earnings Scheduled For August 11, 2021

By Benzinga Insights

Today, 3:47 PM

Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter.

ACVA

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 3:47 PM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

1 minute read

Navidea Stock Gains After FDA Grants End Of Phase 2 Meeting To Discuss Rheumatoid Arthritis Program

By Vandana Singh

Today, 3:47 PM

The FDA has granted Navidea Biopharmaceuticals Inc’s (NYSE:NAVB) request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in…

NAVB

2 minute read

Navidea Biopharmaceuticals Announces End-Of-Phase 2 Type B Meeting Request Granted By FDA To Discuss Ongoing Clinical Program In Rheumatoid Arthritis

By Bill Haddad

Today, 3:47 PM

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the

NAVB